Joakim Nyberg
Joakim Nyberg
Senior Consultant, Pharmetheus, Researcher Pharmacometrics, Uppsala Universitet
Verified email at farmbio.uu.se
Title
Cited by
Cited by
Year
PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool
J Nyberg, S Ueckert, EA Strömberg, S Hennig, MO Karlsson, AC Hooker
Computer methods and programs in biomedicine 108 (2), 789-805, 2012
762012
The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models
J Ribbing, J Nyberg, O Caster, EN Jonsson
Journal of pharmacokinetics and pharmacodynamics 34 (4), 485-517, 2007
652007
Methods and software tools for design evaluation in population pharmacokinetics–pharmacodynamics studies
J Nyberg, C Bazzoli, K Ogungbenro, A Aliev, S Leonov, S Duffull, ...
British journal of clinical pharmacology 79 (1), 6-17, 2015
642015
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models
C Vong, M Bergstrand, J Nyberg, MO Karlsson
The AAPS journal 14 (2), 176-186, 2012
562012
Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients
IK Delattre, FT Musuamba, J Nyberg, FS Taccone, PF Laterre, ...
Therapeutic drug monitoring 32 (6), 749-756, 2010
512010
Simultaneous optimal experimental design on dose and sample times
J Nyberg, MO Karlsson, AC Hooker
Journal of pharmacokinetics and pharmacodynamics 36 (2), 125, 2009
472009
High-spin states in 183Pt
J Nyberg, A Johnson, MP Carpenter, CR Bingham, LH Courtney, ...
Nuclear Physics A 511 (1), 92-116, 1990
461990
Adaptive‐optimal design in PET occupancy studies
S Zamuner, VL Di Iorio, J Nyberg, RN Gunn, VJ Cunningham, R Gomeni, ...
Clinical Pharmacology & Therapeutics 87 (5), 563-571, 2010
352010
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin
S Hennig, J Nyberg, S Fanta, JT Backman, K Hoppu, AC Hooker, ...
The Journal of Clinical Pharmacology 52 (3), 347-360, 2012
222012
Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design
HE Silber, J Nyberg, AC Hooker, MO Karlsson
Journal of pharmacokinetics and pharmacodynamics 36 (3), 281, 2009
222009
Population pharmacokinetics of edoxaban in patients with symptomatic deep‐vein thrombosis and/or pulmonary embolism—the Hokusai‐VTE phase 3 study
R Niebecker, S Jönsson, MO Karlsson, R Miller, J Nyberg, EHJ Krekels, ...
British journal of clinical pharmacology 80 (6), 1374-1387, 2015
192015
A comparison of automatic differentiation and continuous sensitivity analysis for derivatives of differential equation solutions
C Rackauckas, Y Ma, V Dixit, X Guo, M Innes, J Revels, J Nyberg, ...
arXiv preprint arXiv:1812.01892, 2018
182018
A pharmacokinetic-pharmacodynamic model of morphine exposure and subsequent morphine consumption in postoperative pain
RV Juul, J Nyberg, TM Lund, S Rasmussen, M Kreilgaard, LL Christrup, ...
Pharmaceutical research 33 (5), 1093-1103, 2016
152016
Population optimal experimental design for discrete type data
J Nyberg, MO Karlsson, AC Hooker
PAGE (Population Approach Group Europe) 18, Abstr 1468, 2009
142009
Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain
A Taneja, J Nyberg, ECM De Lange, M Danhof, O Della Pasqua
Journal of pharmacokinetics and pharmacodynamics 39 (6), 673-681, 2012
102012
Serial correlation in optimal design for nonlinear mixed effects models
J Nyberg, R Höglund, M Bergstrand, MO Karlsson, AC Hooker
Journal of pharmacokinetics and pharmacodynamics 39 (3), 239-249, 2012
102012
Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment
E Sjögren, J Nyberg, MO Magnusson, H Lennernäs, A Hooker, ...
Drug metabolism and disposition 39 (5), 858-863, 2011
102011
Trial treatment length optimization with an emphasis on disease progression studies
S Hennig, J Nyberg, AC Hooker, MO Karlsson
The Journal of Clinical Pharmacology 49 (3), 323-335, 2009
102009
Edoxaban Exposure‐Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep‐Vein Thrombosis or Pulmonary Embolism
J Nyberg, KE Karlsson, S Jönsson, OQP Yin, R Miller, MO Karlsson, ...
CPT: pharmacometrics & systems pharmacology 5 (4), 222-232, 2016
82016
Inter occasion variability in individual optimal design
AN Kristoffersson, LE Friberg, J Nyberg
Journal of pharmacokinetics and pharmacodynamics 42 (6), 735-750, 2015
72015
The system can't perform the operation now. Try again later.
Articles 1–20